DFF332 as a Single Agent and in Combination With Everolimus & Immuno-Oncology Agents in Advanced/Relapsed Renal Cancer & Other Malignancies
Clinical trial NCT04895748 · TERMINATED
Trial details
- NCT number
- NCT04895748
- Sponsor
- Novartis Pharmaceuticals
- Status
- TERMINATED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2021-11-30
- Primary completion
- 2026-02-13
- Enrollment
- 40
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.